Sanofi Pharma Ltd. | Cash Flow

Fiscal year is January-December. All values INR Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
3,631
3,061
3,970
4,804
5,146
Depreciation, Depletion & Amortization
923
966
1,130
1,188
1,022
Other Funds
1,235
1,247
1,427
2,172
1,942
Funds from Operations
3,319
2,780
3,673
3,820
4,226
Changes in Working Capital
267
364
1,121
12
803
Net Operating Cash Flow
3,052
3,143
2,552
3,808
5,029
Capital Expenditures
1,744
1,272
3,506
693
570
Sale of Fixed Assets & Businesses
2
1,090
3,219
6
5
Purchase/Sale of Investments
238
3
8
-
-
Net Investing Cash Flow
3,684
115
64
2,137
1,465
Cash Dividends Paid - Total
1,046
1,213
1,466
1,802
1,884
Net Financing Cash Flow
1,046
1,213
1,466
1,802
1,884
Net Change in Cash
1,678
2,046
1,021
131
1,680
Free Cash Flow
1,308
1,871
927
3,115
4,459
Other Sources
1,100
1,600
230
-
350
Exchange Rate Effect
-
-
-
-
-
Other Uses
3,280
1,300
-
1,450
1,250

About Sanofi Pharma

View Profile
Address
Sanofi House
Mumbai Maharashtra 400072
India
Employees -
Website http://www.sanofiindialtd.com
Updated 09/14/2018
Sanofi India Ltd. engages in the manufacture and distribution of pharmaceutical drugs. The firm offers its products under the AllStar, Amaryl M, Amaryl M Forte, Amaryl MV, Apidra, Arava, Augeoz, Brodactam, Cardace, Cardace Protect, Cardace AM, Cardace Meto, Caspercid, Cetapin P, Cetapin XR, Cetapin V, Clexane, Daonil, Daonil M, Frisium, Insuman Rapid, Insuman Comb 25, Insuman Comb 50, Lantus, Lasilactone 50 Lasix, Metosan XR, M-Nem, Rejusite, Amaryl, Semi-Daonil, Targocid, Taxotere, Telsite, Telsite AM, Telsite AM H, Telsite H, Trental, Vogsite Md, and Zolineg brands. It also focuses on the following therapeutic areas: diabetes, cardiology, consumer healthcare, hospital, central nervous system, and anti-histamines.